Literature DB >> 30342424

Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases.

Vanesa Nozal1, Ana Martinez2.   

Abstract

Tau-tubuline kinases (TTBK) are a family of serine/threonine and tyrosine kinases recently discovered and implicated in the phosphorylation of important substrates such as tau, tubuline or TDP-43. Its two homologs, TTBK1 and TTBK2, show different expression patterns and different involvements in physiological mechanisms of great importance such as mitosis, ciliogenesis and neurotransmission. Their phosphorylation activity has also linked them to the development of neurodegenerative diseases like Alzheimer's disease, amyotrophic lateral sclerosis or spinocerebellar ataxia type 11. There are currently only three inhibitors of these kinases described in the literature. This review intends to give an overview of the structure, expression, physiological and pathological mechanisms of both kinases as well as an extended analysis on the molecules that can inhibit them. The final analysis of all this information led us to propose TTBK1 as a new target for the treatment of neurodegenerative diseases and its selective inhibitors as potential effective drugs for the treatment of these severe unmet disorders.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyotrophic lateral sclerosis; Drug candidate; Neurodegenerative diseases; TDP-43; TTBK2; Tau tubulin kinase 1 (TTBK1) inhibitor

Mesh:

Substances:

Year:  2018        PMID: 30342424     DOI: 10.1016/j.ejmech.2018.10.030

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  A Risk Score Model Based on Nine Differentially Methylated mRNAs for Predicting Prognosis of Patients with Clear Cell Renal Cell Carcinoma.

Authors:  Jingmin Zhou; Guanghua Liu; Xingcheng Wu; Zhien Zhou; Jialin Li; Zhigang Ji
Journal:  Dis Markers       Date:  2021-01-14       Impact factor: 3.434

Review 2.  Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies.

Authors:  M Catarina Silva; Stephen J Haggarty
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

3.  Subacute and chronic proteomic and phosphoproteomic analyses of a mouse model of traumatic brain injury at two timepoints and comparison with chronic traumatic encephalopathy in human samples.

Authors:  Alexander Morin; Roderick Davis; Teresa Darcey; Michael Mullan; Benoit Mouzon; Fiona Crawford
Journal:  Mol Brain       Date:  2022-07-18       Impact factor: 4.399

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.